The Orphan Drug Privilege and the sales threshold refer to a special rule within the German early benefit assessment for drugs for rare diseases. For an approved orphan drug, the additional medical benefit is initially considered proven by its approval. If sales with statutory health insurance exceed 30 million Euros in the last twelve calendar months, a regular benefit assessment with complete documentation is triggered.
Special Procedure within Early Benefit Assessment
This regulation does not change the orphan drug approval process, but rather the nature of the German additional benefit assessment. For market access, no appropriate comparator therapy is defined as the basis for a regular comparative assessment for a drug for a rare disease. Under the legal provisions, the G-BA assesses the extent of the additional benefit, which is considered to exist, based on the approval documents.
This does not eliminate all substantive evaluation. The submitted studies are still required to classify the extent of the additional benefit for the approved patient populations. However, the legal starting point differs from the standard assessment: the existence of an additional medical benefit is not first proven by a comparison with an appropriate comparator therapy.
Function of the Sales Threshold
The sales threshold is linked to sales with statutory health insurance at pharmacy retail prices, including VAT, in the past twelve calendar months. If this threshold is exceeded, the G-BA requires documentation for a regular benefit assessment. An appropriate comparator therapy is then determined, and the additional benefit is assessed comparatively. The specificities of the initial orphan procedure do not continue to apply for this re-assessment.
For the evidence strategy, this change has significant consequences. Data sufficient for classifying the extent in the limited assessment do not necessarily answer the later comparative question. The relevant care situation may change by the time the threshold is exceeded. Therefore, companies must keep an eye on potential comparator therapies and the development of the treatment algorithm even during the orphan phase.
Distinction: Reimbursement Rule and Orphan Status
The privilege is not a European marketing authorization status. The term Orphan Drug in the existing glossary refers to the designation for medicines for rare diseases and the applicable European authorization and incentive regulations. The privilege described here concerns only the German benefit assessment according to Paragraph 35a SGB V and its legal fiction of proof.
Neither a conditional marketing authorization nor an authorization under exceptional circumstances is synonymous with the privilege. These authorization forms concern the data situation at the time of marketing authorization. The Orphan Drug Privilege, however, addresses how the additional benefit is treated in the German reimbursement assessment up to the sales threshold.
The transition beyond the sales threshold is not a re-assessment of market authorization. It triggers a different evidence requirement within the reimbursement system. Upon request by the G-BA, the company must submit the legally required documents within the specified deadline. Therefore, preparation involves not only sales forecasts but also the availability of evaluable clinical data for the then-relevant comparator therapy. A gap in evidence cannot be justified by orphan status once the regular procedure has been initiated.
Furthermore, sales are not to be equated with worldwide sales or a list price. The legally defined GKV-related sales in the preceding twelve-month period are decisive. The threshold is therefore not a measure of medical significance or the number of people treated. It exclusively determines at what point the German standard assessment, with comparator therapy and complete evidence, intervenes.
For ongoing projects, threshold monitoring is therefore an interface between market access, controlling, and clinical evidence planning. It must not begin only when the G-BA requests complete documentation.
The regulation thus combines an easier entry into the assessment with a potentially later comparative assessment. It does not permanently privilege the evidence requirement but defines the point at which the full assessment mechanism comes into play.
Relevance for clinical trials
For rare diseases, small populations and a limited range of comparators are often central. The privilege does not eliminate these development problems but shifts the assessment mechanism at market entry. Study documents must document the approved population and patient-relevant results in such a way that the extent of the additional benefit can be classified; at the same time, later comparative evidence should not disappear from the planning horizon.
Full-service CROs like Mediconomics support by evaluating approval studies for the orphan dossier structure and through long-term evidence planning for a potential threshold transition. Regulatory Affairs, Medical Writing, and Biostatistics can integrate approval data, patient numbers, and potential comparator options to prepare for a transition to regular assessment.
Frequently Asked Questions (FAQ)
Does every benefit assessment for an orphan drug cease?
No. The additional benefit is initially considered proven, but its extent is still assessed in the procedure based on the available documentation.
Is an appropriate comparator therapy defined before the sales threshold?
In the limited orphan procedure, no comparator therapy is defined as the basis for a regular additional benefit assessment.
Is the sales threshold a European orphan criterion?
No. It is a rule of German law for early benefit assessment and not part of the European orphan designation.
Regulatory References
- Paragraph 35a, Section 1 SGB V – contains privilege and sales threshold for orphan drugs.
- Regulation (EC) No. 141/2000 – regulates the European designation for medicines for rare diseases.
- IQWiG, General Methods Version 8.0 – describes the orphan special case in the context of assessment.
- Rules of Procedure of the G-BA, Chapter 5 – specifies the benefit assessment of medicinal products.